Bulletin 13 | May 2024
Snapshots
BOMBAY HIGH COURT
DAIWA PHARMACEUTICALS CO. LTD. V. DAIWA PHARMACEUTICALS PVT. LTD. & ORS.
DELHI HIGH COURT
GOOGLE LLC V. CONTROLLER OF PATENTS
The Delhi HC upheld the Indian Patent Officer’s rejection of a patent application for a messaging system, citing lack of novelty and inventive step over prior arts.
The Court noted that the Appellant claimed differentiating features but failed to disclose that the corresponding EU patent application was rejected, not abandoned. Information about a subsequent divisional application being rejected was also withheld by the Appellant.
While dismissing the appeal, the Court imposed a cost of INR 1 lakh on the Appellant for non-compliance with disclosure requirements under the Patents Act viz. non- disclosure of rejections of the EU patent applications and for stating wrong facts before the Court.
CALCUTTA HIGH COURT
EMAMI LTD. V. HINDUSTAN UNILEVER LTD.
COMMERCIAL COURT, BENGALURU
M/S BETWEEN SPACES v. AKSHADHAA ASSISTED LIVING ESTABLISHMENT LLP
DELHI HIGH COURT
M/S. P.M. DIESELS P. LTD. V. M/S. THUKRAL MECHANICAL WORKS & ORS. (& CONNECTED PETITIONS)
This trademark dispute saw an end after 40 years of legal battle, whereby the Court concluded that P.M. Diesels was the prior adopter, prior user and legitimate owner of the mark “FIELDMARSHAL”. The Court further cancelled the registrations of the said mark in favour of the Defendants, and passed a decree for actual costs in favour of P.M. Diesels given that the litigation between the parties had imposed substantial financial burden on them to protect and defend their mark.
Significant Judgments
DELHI HIGH COURT
HEIFER PROJECT INTERNATIONAL V. HEIFER PROJECT INDIA TRUST.
30. Indeed, the present case is a classic instance of ‘triple identity.’ The Impugned trademarks are nearly identical, as are the areas of operation, and the segments of the public they target. Therefore, the Defendants’ use of these nearly identical and deceptively similar marks is certain to cause deception and confusion among the general public.
SUPREME COURT OF INDIA
YASHRAJ FILMS PVT. LTD. V. AFREEN FATIMA ZAIDI & ANR.
“17… A false representation is one that is false in substance and in fact, and the test by which the representation must be judged is to see whether the discrepancy between the represented fact and the actual fact would be considered material by a reasonable person.”
DELHI HIGH COURT (DB)
NATCO PHARMA V. NOVARTIS AG AND ANR.
- Defendant neither has a heavy burden to discharge, nor needs to establish a strong prima facie case to challenge patent validity.
- Section 3(d) sets a higher invention threshold for medicines/drugs, excluding new forms of known substances without significantly different efficacy. Enhanced solubility/bioavailability alone does not constitute higher therapeutic efficacy under Section 3(d).
- No permissible dichotomy between patent coverage and disclosure; would negate fundamental patent grant rules.
- Submissions during patent term extensions in other countries relevant, at least at interim stage.
98. There is no ambiguity in the aforesaid decision that there cannot be dichotomy between coverage or claim on one hand and the disclosure on the other.
Meet the Picklers
Sneha Jain, Savni D. Endlaw, Snehima Jauhari, Kuber Mahajan, Saif Rahman Ansari, Disha Sharma and Srishti Dhoundiyal.


